Literature DB >> 22699224

[Management of patients with pulmonary hypertension].

B Preckel1, S Eberl, J Fräßdorf, M W Hollmann.   

Abstract

Due to the increased survival of patients with pulmonary hypertension, even non-cardiac anesthesiologists will see these patients more frequently for anesthesia. The hemodynamic goal in the perioperative period is to avoid an increase in pulmonary vascular resistance (PVR) and to reduce a possibly pre-existing elevated PVR. Acute increases of chronically elevated PVR may result from hypoxia, hypercapnia, acidosis, hypothermia, elevated sympathetic output and also release of endogenous or application of exogenous pulmonary vasoconstrictors. Early recognition and treatment of these changes might be life saving in these patients. Drug interventions to perioperatively reduce PVR include administration of pulmonary vasodilators, such as oxygen, prostacyclines (epoprostenol, iloprost), phosphodiesterase III (milrinone) and V (sildenafil) inhibitors, as well as nitrates and nitric oxide. Along with the concept of selective pulmonary vasodilation inhalative administration of pulmonary vasodilators has benefits compared to intravenous administration. New therapeutic strategies, such as inhalational iloprost, inhalational milrinone and intravenous sildenafil can be introduced without significant technical support even in smaller departments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699224     DOI: 10.1007/s00101-012-2040-2

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  76 in total

Review 1.  Updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

2.  Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

Authors:  Vallerie V McLaughlin; Raymond L Benza; Lewis J Rubin; Richard N Channick; Robert Voswinckel; Victor F Tapson; Ivan M Robbins; Horst Olschewski; Melvyn Rubenfire; Werner Seeger
Journal:  J Am Coll Cardiol       Date:  2010-05-04       Impact factor: 24.094

Review 3.  Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective.

Authors:  Mardi Gomberg-Maitland; Christopher Dufton; Ronald J Oudiz; Raymond L Benza
Journal:  J Am Coll Cardiol       Date:  2011-03-01       Impact factor: 24.094

4.  Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome.

Authors:  H Gerlach; R Rossaint; D Pappert; K J Falke
Journal:  Eur J Clin Invest       Date:  1993-08       Impact factor: 4.686

Review 5.  [The effect of sedation on pulmonary function].

Authors:  K Wiedemann; C Diestelhorst
Journal:  Anaesthesist       Date:  1995-12       Impact factor: 1.041

6.  Preliminary experience with inhaled milrinone in cardiac surgery.

Authors:  Yoan Lamarche; Louis P Perrault; Simon Maltais; Karine Tétreault; Jean Lambert; André Y Denault
Journal:  Eur J Cardiothorac Surg       Date:  2007-04-02       Impact factor: 4.191

7.  Perioperative mortality in patients with pulmonary hypertension undergoing major joint replacement.

Authors:  Stavros G Memtsoudis; Yan Ma; Ya Lin Chiu; J Matthias Walz; Robert Voswinckel; Madhu Mazumdar
Journal:  Anesth Analg       Date:  2010-09-14       Impact factor: 5.108

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial.

Authors:  S Rex; G Schaelte; S Metzelder; S Flier; E E C de Waal; R Autschbach; R Rossaint; W Buhre
Journal:  Acta Anaesthesiol Scand       Date:  2007-11-01       Impact factor: 2.105

Review 10.  Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.

Authors:  Ronald J Oudiz; Harrison W Farber
Journal:  Am Heart J       Date:  2009-04       Impact factor: 4.749

View more
  3 in total

Review 1.  Pulmonary hypertension and cardiac anesthesia: Anesthesiologist's perspective.

Authors:  Manjula Sudeep Sarkar; Pushkar M Desai
Journal:  Ann Card Anaesth       Date:  2018 Apr-Jun

2.  Perioperative anesthesiological management of patients with pulmonary hypertension.

Authors:  Jochen Gille; Hans-Jürgen Seyfarth; Stefan Gerlach; Michael Malcharek; Elke Czeslick; Armin Sablotzki
Journal:  Anesthesiol Res Pract       Date:  2012-10-12

3.  Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations.

Authors:  Hans-Jürgen Seyfarth; Jochen Gille; Armin Sablotzki; Stefan Gerlach; Michael Malcharek; Andreas Gosse; Ralf H Gahr; Elke Czeslick
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2015-01-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.